Company News for Mar 16, 2026
- Adobe Inc.’s (ADBE) shares tumbled 7.6%, after the company announced that its longtime CEO Shantanu Narayen will step down once a successor is appointed.
- Shares of Meta Platforms Inc. (META) slid 3.8% following news that the company has delayed the release of its new AI model "Avocado" to at least May.
- Shares of Nektar Therapeutics (NKTR) surged 4.1% after reporting fourth-quarter 2025 adjusted loss of $1.78 per share, narrower than the Zacks Consensus Estimate of an adjusted loss of $2.76 per share.
- Oruka Therapeutics Inc.’s (ORKA) shares soared 25% after posting fourth-quarter 2025 adjusted loss of $0.45 per share, narrower than the Zacks Consensus Estimate of an adjusted loss of $0.61 per share.
Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Adobe Inc. (ADBE): Free Stock Analysis Report
Nektar Therapeutics (NKTR): Free Stock Analysis Report
Meta Platforms, Inc. (META): Free Stock Analysis Report
Oruka Therapeutics, Inc. (ORKA): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners. Copyright 2006-2026 Zacks Equity Research, Inc. editor@zacks.com (Manaing editor) webmaster@zacks.com (Webmaster)
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments
No comments yet